M. Dvorkin

发表

De novo protein sequencing by combining top-down and bottom-up tandem mass spectra.

P. Pevzner, L. Paša-Tolić, T. Luider, 2014, Journal of proteome research.

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

A. Oza, I. Bondarenko, N. Colombo, 2022, The Lancet. Oncology.

New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?

L. Byers, M. Dvorkin, Bingnan Zhang, 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Efficacy of Sym 004 in PatientsWithMetastatic Colorectal CancerWith Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNAAnalyses A Phase 2 Randomized Clinical Trial

C. Nadal, R. Salazar, A. Bardelli, 2018 .

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Y. Bang, Z. Wainberg, J. Taieb, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

K. Harrington, N. Lee, R. Ferris, 2021, The Lancet. Oncology.

E. Van Cutsem, J. Tabernero, M. Alsina, 2020, Gastric Cancer.

PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

N. Reinmuth, Y. Shrestha, Haiyi Jiang, 2019, Annals of Oncology.

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

G. Beretta, E. Van Cutsem, J. Tabernero, 2021, Gastric Cancer.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

a of Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN):

N. Reinmuth, N. Shire, Haiyi Jiang, 2020 .

Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

Y. Shu, M. Dvorkin, Jie-Xie Wang, 2022 .

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

G. Yancopoulos, I. Lowy, D. Weinreich, 2022, Nature Medicine.

Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).

G. Beretta, J. Tabernero, M. Alsina, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Ferris, T. Ciuleanu, B. Keam, 2019, Journal of Clinical Oncology.

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, Journal of Clinical Oncology.

SPAdes: A New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing

Sergey I. Nikolenko, Dmitry Antipov, Andrey D. Prjibelski, 2012, J. Comput. Biol..

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.

G. Beretta, E. Van Cutsem, J. Tabernero, 2018, The Lancet. Oncology.

Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer.

M. Edelman, A. Navarro, A. Dowlati, 2022, Lung cancer.

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

R. Ferris, T. Ciuleanu, B. Keam, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

A. Oza, I. Bondarenko, N. Colombo, 2021 .

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

C. Nadal, R. Salazar, A. Bardelli, 2018, JAMA oncology.

Abstract P1-19-03: JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts

M. Galsky, A. Bardia, C. Chappey, 2020 .

Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial.

Ying Cheng, Y. Shu, M. Dvorkin, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

Z. Bashir, K. Syrigos, V. Sriuranpong, 2021, BioDrugs.

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

N. Reinmuth, N. Shire, Haiyi Jiang, 2020, Lung cancer.

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, The Lancet. Oncology.

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.

Ying Cheng, Xuhong Min, Yanqiu Zhao, 2022, JAMA.

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.

A. Ananthakrishnan, J. Reguła, D. Rubin, 2021, The lancet. Gastroenterology & hepatology.

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, European journal of cancer.